Top

Published in:

Open Access 01-07-2016 | Original Article

A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma

Authors: Hironaga Satake, Makoto Tahara, Satoshi Mochizuki, Ken Kato, Hiroki Hara, Tomoya Yokota, Naomi Kiyota, Takayuki Kii, Keisho Chin, Sadamoto Zenda, Takashi Kojima, Hideaki Bando, Tomoko Yamazaki, Satoru Iwasa, Yoshitaka Honma, Satoru Hamauchi, Takahiro Tsushima, Atsushi Ohtsu

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2016

Abstract

Purpose

Standard care for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) is concurrent chemoradiotherapy, but survival remains limited. Neoadjuvant chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) has demonstrated promising activity, with a pathological complete response (CR) of 17 % for resectable stage II/III ESCC. Here, we conducted a multicenter study to assess the efficacy and safety of induction chemotherapy with DCF followed by CRT in patients with unresectable locally advanced ESCC.

Methods

Eligibility criteria included clinical T4 and/or M1 lymph node ESCC, PS 0–1 and age 20–70 years. Treatment consisted of docetaxel 70 mg/m² and cisplatin 70 mg/m² on day 1, and fluorouracil 750 mg/m² on days 1–5, repeated every 3 weeks for three cycles, followed by cisplatin 70 mg/m² on days 64 and 92, and fluorouracil 700 mg/m² on days 64–67 and 92–95, concurrently with radiotherapy (60 Gy in 30 fractions, 5 days/week). Primary endpoint of the phase II part was CR rate.

Results

Thirty-three patients were enrolled. The completion rate of protocol treatment was 88 %. Thirteen patients (39.4 %) achieved a CR. With a median follow-up period of 41 months (range 24–49 months), median progression-free survival was 12.2 months, and median survival was 26.0 months, with a survival rate of 40.4 % at 3 years. The most common grade 3 or 4 toxicities were neutropenia, leukopenia, anorexia and dysphagia. No treatment-related death was observed.

Conclusion

Induction chemotherapy with DCF followed by CRT is tolerable and shows promising efficacy for unresectable locally advanced ESCC.

Sagar PM, Gauperaa T, Sue-Ling H, McMahon MJ, Johnston D (1994) An audit of the treatment of cancer of the oesophagus. Gut 35(7):941–945CrossRefPubMedPubMedCentral

Ikeda K, Ishida K, Sato N, Koeda K, Aoki K, Kimura Y, Iwaya T, Ogasawara S, Iijima S, Nakamura R, Uesugi N, Maesawa C, Saito K (2001) Chemoradiotherapy followed by surgery for thoracic esophageal cancer potentially or actually involving adjacent organs. Dis Esophagus 14(3–4):197–201CrossRefPubMed

Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34(10):615–619. doi:10.1093/jjco/hyh107 CrossRefPubMed

Matsubara T, Ueda M, Kokudo N, Takahashi T, Muto T, Yanagisawa A (2001) Role of esophagectomy in treatment of esophageal carcinoma with clinical evidence of adjacent organ invasion. World J Surg 25(3):279–284. doi:10.1007/s002680020060 CrossRefPubMed

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25(10):1160–1168. doi:10.1200/JCO.2005.04.7118 CrossRefPubMed

Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593–1598. doi:10.1056/NEJM199206113262403 CrossRefPubMed

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17):1623–1627CrossRefPubMed

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17(9):2915–2921PubMed

Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, Kosugi S, Toh Y, Nakamura K, Fukuda H, Japan Clinical Oncology G (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106(4):407–412. doi:10.1111/cas.12622 CrossRefPubMedPubMedCentral

10.

Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le BN, Clavel M, Kaye SB (1994) Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5(6):533–537PubMed

11.

Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14(5):1672–1678PubMed

12.

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357(17):1705–1715. doi:10.1056/NEJMoa070956 CrossRefPubMed

13.

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357(17):1695–1704. doi:10.1056/NEJMoa071028 CrossRefPubMed

14.

Hara H, Tahara M, Daiko H, Kato K, Igaki H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M, Hosoya Y (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104(11):1455–1460. doi:10.1111/cas.12274 CrossRefPubMed

15.

Chiarion-Sileni V, Corti L, Ruol A, Innocente R, Boso C, Del Bianco P, Pigozzo J, Mazzarotto R, Tomassi O, Ancona E (2007) Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer. Br J Cancer 96(3):432–438. doi:10.1038/sj.bjc.6603585 CrossRefPubMedPubMedCentral

16.

Japanese classification of esophageal cancer, 10th ed (2008). Parts II and III. Esophagus 6(2):71–94

17.

Nakamura T, Hayashi K, Ota M, Eguchi R, Ide H, Takasaki K, Mitsuhashi N (2004) Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg 188(3):261–266. doi:10.1016/j.amjsurg.2004.06.003 CrossRefPubMed

18.

Tomimaru Y, Yano M, Takachi K, Miyashiro I, Ishihara R, Nishiyama K, Sasaki Y, Ishikawa O, Doki Y, Imaoka S (2006) Factors affecting the prognosis of patients with esophageal cancer undergoing salvage surgery after definitive chemoradiotherapy. J Surg Oncol 93(5):422–428. doi:10.1002/jso.20475 CrossRefPubMed

19.

Swisher SG, Wynn P, Putnam JB, Mosheim MB, Correa AM, Komaki RR, Ajani JA, Smythe WR, Vaporciyan AA, Roth JA, Walsh GL (2002) Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 123(1):175–183CrossRefPubMed

20.

Yano T, Muto M, Hattori S, Minashi K, Onozawa M, Nihei K, Ishikura S, Ohtsu A, Yoshida S (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40(9):717–721. doi:10.1055/s-2008-1077480 CrossRefPubMed

21.

Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Seriu T (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272. doi:10.1007/s00280-010-1422-x CrossRefPubMed

22.

Muro K (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959. doi:10.1093/annonc/mdh231 CrossRefPubMed

23.

Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, Koizumi W, Kitasato Digestive D, Oncology G (2014) Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase II trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys 89(4):872–879. doi:10.1016/j.ijrobp.2014.03.030 CrossRefPubMed

24.

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174CrossRefPubMed

25.

Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, Koba I, Shimizu W, Ogino T (1995) Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 25(6):261–266PubMed

Title: A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma
Authors: Hironaga Satake
Makoto Tahara
Satoshi Mochizuki
Ken Kato
Hiroki Hara
Tomoya Yokota
Naomi Kiyota
Takayuki Kii
Keisho Chin
Sadamoto Zenda
Takashi Kojima
Hideaki Bando
Tomoko Yamazaki
Satoru Iwasa
Yoshitaka Honma
Satoru Hamauchi
Takahiro Tsushima
Atsushi Ohtsu
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-3062-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Effect of renal function on pemetrexed-induced haematotoxicity

Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1

Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation

Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors

Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites

Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer